Dana-Farber Cancer Institute | Strategic Alliance Partners

January 04, 2021

Ian E. Krop, MD, PhD, highlights the impact of the pivotal KATHERINE trial on the adjuvant treatment of patients with early-stage HER2-positive breast cancer and other recent advances that are moving the needle forward.

December 22, 2020

December 22, 2020 — Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor–positive, estrogen receptor–positive metastatic breast cancer.

December 16, 2020

Mehmet K. Samur, PhD, discusses the evolving treatment landscape in multiple myeloma.

December 15, 2020

Lajos Pusztai, MD, DPhil, discusses the role of circulating tumor DNA as a biomarker of response in patients with high-risk early-stage breast cancer.

December 15, 2020

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of pevonedistat in myelodysplastic syndrome.

December 08, 2020

Ursula A. Matulonis, MD, discusses the need to improve responses to immunotherapy among patients with recurrent gynecologic cancers.

November 25, 2020

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

November 23, 2020

November 24, 2020 — Amcenestrant, a new oral form of endocrine therapy that has shown early signs of efficacy, is being evaluated against the current standards of care in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

November 11, 2020

Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.

November 10, 2020

Dana-Farber/Brigham and Women’s Cancer Center​​​ ​formally announced an exclusive, expanded collaboration to increase access to DF/BWCC experts and resources for patients at Stamford Health’s Carl & Dorothy Bennett Cancer Center.

November 09, 2020

Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.

November 09, 2020

Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.

November 03, 2020

Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.

October 27, 2020

Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.

October 27, 2020

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

October 26, 2020

Adagrasib, a potent and selective inhibitor of KRAS G12C, showcased encouraging clinical activity with an acceptable safety profile in patients with KRAS G12C–positive non–small cell lung cancer, colorectal cancer, and other solid tumors.

October 26, 2020

Caron Jacobson, MD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.

October 23, 2020

Sara M. Tolaney, MD, MPH, discusses escalating versus de-escalating therapies in HER2-positive breast cancer.

October 22, 2020

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

October 16, 2020

Sara M. Tolaney, MD, MPH, discusses the challenges in treating patients with heterogenous HER2 expression and what treatments could potentially improve outcomes for this subgroup.